Linsitinib
Linsitinib is an oral, ATP-competitive dual IGF-1R and insulin receptor (InsR) inhibitor, blocking ligand-stimulated receptor autophosphorylation and downstream IRS-1/PI3K/AKT signalling. IGF-1R co-inhibition with InsR prevents the compensatory hyperinsulinaemia-driven InsR activation that limits selective IGF-1R inhibitors. Active in Ewing sarcoma and adrenocortical carcinoma models.
Description
Scientific Overview: Linsitinib is an oral, ATP-competitive dual IGF-1R and insulin receptor (InsR) inhibitor, blocking ligand-stimulated receptor autophosphorylation and downstream IRS-1/PI3K/AKT signalling. IGF-1R co-inhibition with InsR prevents the compensatory hyperinsulinaemia-driven InsR activation that limits selective IGF-1R inhibitors. Active in Ewing sarcoma and adrenocortical carcinoma models.
Mechanism of Action: IGF-1R / InsR Dual Inhibitor
Purity: ≥99% | Molecular Formula: C20H17N5O
For Research Use Only. Not intended for diagnostic, therapeutic, or clinical applications.
Additional information
| Effect | IGF-1R / InsR Dual Inhibitor |
|---|---|
| Purity | ≥99% |
| Molecular Formula | C20H17N5O |
| CAS Number | 867160-71-2 |
